A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells

(2020) Abel Soto-Gamez et al.   Cancers

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

(2020) Junnan Li et al.   Cancers

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

(2019) Mohamed I Saad et al.   EMBO Molecular Medicine

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

(2019) Silvia La Monica et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

(2018) Chiara Tomasello et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

(2018) Zheng Yang et al.   International Journal of Biological Sciences

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

Third generation EGFR TKIs: current data and future directions

(2018) Chee-Seng Tan et al.   Molecular Cancer

The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance

(2018) Shang Yao et al.   SEMINARS IN CANCER BIOLOGY

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

(2018) Tatsuya Nagano et al.   Cells

Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo

(2017) Jie Ye et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

(2017) Antonio Passaro et al.   PHARMACOLOGICAL RESEARCH

Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer

(2016) A. Sharma et al.   CLINICAL CANCER RESEARCH

Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance

(2016) Gabriela Nestal de Moraes et al.   CURRENT DRUG TARGETS

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways

(2015) J. Rios-Doria et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation

(2014) Yanchao Huang et al.   International Journal of Biological Sciences

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy

(2014) Hang Fai Kwok et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance

(2013) Ana R. Gomes et al.   Chinese Journal of Cancer

FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy

(2011) Miranda S.C. Wilson et al.   CURRENT DRUG TARGETS

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Animal Research: ReportingIn VivoExperiments: The ARRIVE guidelines

(2010)   EXPERIMENTAL PHYSIOLOGY

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

ADAM17 as a Therapeutic Target in Multiple Diseases

(2009) Joaquin Arribas et al.   CURRENT PHARMACEUTICAL DESIGN

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments

(2009) Hiromi Kataoka   JOURNAL OF DERMATOLOGICAL SCIENCE

Current perspective of TACE inhibitors: A review

(2008) Shirshendu DasGupta et al.   BIOORGANIC & MEDICINAL CHEMISTRY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

The ADAM metalloproteinases

(2008) D EDWARDS et al.   MOLECULAR ASPECTS OF MEDICINE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA